ATRI vs. OSUR, ANIK, CERS, UTMD, ICUI, TMCI, SILK, SIBN, KIDS, and EMBC
Should you be buying Atrion stock or one of its competitors? The main competitors of Atrion include OraSure Technologies (OSUR), Anika Therapeutics (ANIK), Cerus (CERS), Utah Medical Products (UTMD), ICU Medical (ICUI), Treace Medical Concepts (TMCI), Silk Road Medical (SILK), SI-BONE (SIBN), OrthoPediatrics (KIDS), and Embecta (EMBC). These companies are all part of the "surgical & medical instruments" industry.
OraSure Technologies (NASDAQ:OSUR) and Atrion (NASDAQ:ATRI) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, dividends, profitability, valuation, community ranking, institutional ownership, earnings, media sentiment and analyst recommendations.
93.5% of OraSure Technologies shares are owned by institutional investors. Comparatively, 66.2% of Atrion shares are owned by institutional investors. 3.4% of OraSure Technologies shares are owned by company insiders. Comparatively, 22.8% of Atrion shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
OraSure Technologies has a net margin of 13.23% compared to OraSure Technologies' net margin of 11.46%. Atrion's return on equity of 14.50% beat OraSure Technologies' return on equity.
OraSure Technologies has higher revenue and earnings than Atrion. OraSure Technologies is trading at a lower price-to-earnings ratio than Atrion, indicating that it is currently the more affordable of the two stocks.
In the previous week, OraSure Technologies had 5 more articles in the media than Atrion. MarketBeat recorded 6 mentions for OraSure Technologies and 1 mentions for Atrion. Atrion's average media sentiment score of 0.28 beat OraSure Technologies' score of 0.13 indicating that OraSure Technologies is being referred to more favorably in the media.
OraSure Technologies currently has a consensus target price of $6.38, suggesting a potential upside of 20.06%. Given Atrion's higher possible upside, equities research analysts plainly believe OraSure Technologies is more favorable than Atrion.
OraSure Technologies received 419 more outperform votes than Atrion when rated by MarketBeat users. Likewise, 69.90% of users gave OraSure Technologies an outperform vote while only 55.60% of users gave Atrion an outperform vote.
OraSure Technologies has a beta of 0.23, meaning that its share price is 77% less volatile than the S&P 500. Comparatively, Atrion has a beta of 0.62, meaning that its share price is 38% less volatile than the S&P 500.
Summary
OraSure Technologies beats Atrion on 12 of the 17 factors compared between the two stocks.
Get Atrion News Delivered to You Automatically
Sign up to receive the latest news and ratings for ATRI and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ATRI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
